Obesity Science & Practice最新文献

{"title":"Changes in Health-Related Quality of Life After Metabolic and Bariatric Surgery: A Prospective Single-Center Cohort Study.","authors":"Camilla Thorbøll Wæhrens, Ingrid Poulsen, Thomas Kallemose, Bodil Just Christensen, Inge Marie Poulsen, Julie Jacoby Petersen, Dorthe Greve Jørgensen, Carsten Dirksen","doi":"10.1002/osp4.70145","DOIUrl":"10.1002/osp4.70145","url":null,"abstract":"<p><strong>Objective: </strong>Obesity impairs health-related quality-of-life (HRQoL). Substantial weight loss following metabolic and bariatric surgery improves HRQoL, but there is a need for larger long-term studies. This study aimed to examine changes in HRQoL at 2 and 5 years, comparing outcomes between Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG), and to evaluate associations with pre-operative patient characteristics.</p><p><strong>Methods: </strong>HRQoL was assessed using the Short Form-36 (SF-36) questionnaire before surgery and at 2- and 5-year follow-up. Physical and Mental Component Scores (PCS and MCS) were calculated, and associations between baseline characteristics and changes in HRQoL were analyzed.</p><p><strong>Results: </strong>Of 2031 patients, 1285 completed at least one postoperative SF-36. PCS improved significantly at 2 years (mean 9.4, 95% CI 8.7-10.0) and was maintained at 5 years. MCS showed an improvement at 2 years (1.5, 95% CI 0.8-2.2) but not at 5 years. No major differences were found between RYGB and SG, except for lower MCS at 5 years in SG patients (5.2, <i>p</i> = 0.009). Preoperative type 2 diabetes and osteoarthritis were associated with improved HRQoL, whereas psychiatric and gastrointestinal disorders predicted poorer results.</p><p><strong>Conclusions: </strong>Metabolic and bariatric surgery leads to sustained improvements in physical HRQoL, but the response is influenced by preoperative comorbidity.</p>","PeriodicalId":19448,"journal":{"name":"Obesity Science & Practice","volume":"12 2","pages":"e70145"},"PeriodicalIF":2.5,"publicationDate":"2026-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13087433/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147723333","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends and Disparities in Obesity-Related Mortality Among U.S. Adults: A CDC WONDER Analysis (1968-2025).","authors":"Faizan Ahmed, Husnain Ahmed, Ayesha Ishtiaq, Najam Gohar, Anika Goel, Abdul Waheed, Tehmasp Rehman Mirza, Haris Bin Tahir, Fatima Saleemi, Tallal Mushtaq Hashmi, Ramsha Ali, Hritvik Jain, Mushood Ahmed, Farah Deshmukh, Mohamed Bakr, Swapnil Patel, Mohammad Hossain, Ameer Haider Cheema","doi":"10.1002/osp4.70146","DOIUrl":"10.1002/osp4.70146","url":null,"abstract":"<p><strong>Context: </strong>Obesity-related mortality in the United States has increased substantially over recent decades, yet long-term national trends and demographic disparities remain incompletely characterized.</p><p><strong>Objective: </strong>To evaluate nationwide trends in obesity-related mortality among U.S. adults and identify disparities by age, sex, race, and geographic region from <i>1968 to 2025</i>.</p><p><strong>Methods: </strong>We performed a retrospective analysis using CDC WONDER mortality data from 1968 to 2025 (nearly six decades). Adults aged ≥ 25 years with obesity identified using International Classification of Diseases (ICD) codes listed as an underlying or contributing cause of death were included. Age-adjusted mortality rates (AAMRs) per 100,000 population were calculated using the 2000 U.S. standard population, and temporal trends were evaluated using Joinpoint regression to estimate annual percent change (APC) and average annual percent change (AAPC).</p><p><strong>Results: </strong>From 1968 to 2025, a total of 211,479 obesity-related deaths were recorded among U.S. adults aged ≥ 25 years. AAMRs increased from 1.15 to 3.32 per 100,000, peaking in 2021 (4.54 per 100,000). Mortality rates were consistently higher among males, older adults, Black populations, and residents of the Southern United States, while younger adults (25-44 years) experienced the most rapid rise in mortality.</p><p><strong>Conclusion: </strong>Obesity-related mortality in the United States has more than tripled over nearly six decades, with substantial demographic and geographic disparities. These findings highlight the urgent need for targeted, culturally tailored, and age-specific public health interventions to address the growing burden of obesity.</p>","PeriodicalId":19448,"journal":{"name":"Obesity Science & Practice","volume":"12 2","pages":"e70146"},"PeriodicalIF":2.5,"publicationDate":"2026-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13080113/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147699242","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Human Monoacylglycerol Acyltransferase 2 Inhibitor VB-85387 Is Associated With Weight Loss in Mice With Obesity.","authors":"J Jose Corbalan, Pranavi Jagadeesan, Chia-Yu Huang, James R Beasley, Joseph T Nickels","doi":"10.1002/osp4.70131","DOIUrl":"10.1002/osp4.70131","url":null,"abstract":"<p><strong>Background: </strong>GLP-1 therapies for obesity are limited by side effects and weight regain is common after treatment ends. Therefore, alternative treatments with new mechanisms are needed for sustained weight loss. Human MOGAT2 regulates triglyceride metabolism and its inhibition reduces weight in people with obesity, making MOGAT2 a promising target for obesity therapy.</p><p><strong>Objective: </strong>This study evaluated the therapeutic potential of the VB-85387 MOGAT2 inhibitor for weight loss.</p><p><strong>Methods: </strong>High throughput screening was used to identify human MOGAT2 inhibitors. Diet-induced mice with obesity were treated with VB-85387 for 7 days. Body weight, food intake, blood and liver lipid and hormone levels were assessed. Glucose tolerance and insulin sensitivity were evaluated via oral glucose tolerance and hyperinsulaemic-euglycaemic clamp tests. Gene expression of PPARα and SREBP target genes was measured using <i>q</i>RT-PCR.</p><p><strong>Results: </strong>High throughput screening identified VB-85387 as a highly potent and selective human MOGAT2 inhibitor. Mice with obesity treated with VB-85387 experienced weight loss, reduced food intake, improved glucose tolerance, and enhanced insulin sensitivity. Treatment decreased liver triglyceride levels and increased GLP-1 concentrations. <i>β</i>-hydroxybutyrate levels were elevated, PPARα-dependent fatty acid <i>β</i>-oxidation gene expression was increased, and SREBP-dependent gene expression was reduced.</p><p><strong>Conclusion: </strong>VB-85387 serves as a starting point for medicinal chemistry lead optimization. Weight loss may be attributed to PPARα activation and a sustained elevation in GLP-1 levels.</p>","PeriodicalId":19448,"journal":{"name":"Obesity Science & Practice","volume":"12 2","pages":"e70131"},"PeriodicalIF":2.5,"publicationDate":"2026-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13066718/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147675460","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeting Multiple Gut-Brain Pathways in Obesity: Rationale for Combination Pharmacotherapy.","authors":"Alexander D Miras, Muzamil Hussain","doi":"10.1002/osp4.70141","DOIUrl":"10.1002/osp4.70141","url":null,"abstract":"<p><strong>Background: </strong>As a disease of energy dysregulation, obesity involves metabolic, hormonal, and neural factors, the interconnection of which is referred to as the \"gut-brain axis.\"</p><p><strong>Objective: </strong>This review aimed to provide an overview of the clinical evidence of physiological and objective or subjective changes in eating behavior with gut hormone analogs and NB-ER, as well as a mechanistic rationale for the combined use of these medications to target multiple pathways along the gut-brain axis, particularly for patients who have not achieved their health goals with a single medication.</p><p><strong>Findings: </strong>Peripheral hormones such as glucagon-like peptide-1 (GLP-1) are released in response to food consumption. Peripheral signals are integrated in the hypothalamus and hindbrain to promote energy homeostasis. These brain regions also interact with other systems such as the mesolimbic dopamine system, which promotes food intake for its rewarding properties. Thus, medical interventions for obesity, such as pharmacotherapy and bariatric surgery, aim to regulate various components of this gut hormone-hedonic brain axis. Gut hormone analog medications such as liraglutide, semaglutide, and tirzepatide target the GLP-1 receptor, with tirzepatide also targeting the glucose-dependent insulinotropic polypeptide receptor. These gut hormone analog medications primarily exert their effects on the hypothalamus and brainstem to reduce energy intake. Evidence on their effects on the reward system and reward-based eating is inconsistent. The fixed-dose, extended-release combination of naltrexone and bupropion (NB-ER) acts via the hypothalamic and mesolimbic systems to reduce food intake and reward-based eating.</p><p><strong>Conclusion: </strong>The distinct yet complementary effects of gut hormone analog medications and NB-ER on gut-brain pathways regulating satiety, hunger, and reward provide a mechanistic rationale for their combination in obesity treatment.</p>","PeriodicalId":19448,"journal":{"name":"Obesity Science & Practice","volume":"12 2","pages":"e70141"},"PeriodicalIF":2.5,"publicationDate":"2026-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13052175/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147633966","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optimizing Obesity Management With GLP-1 Agonist Medication Through Mobile Health Technology, Nutrition Therapy, and Progressive Strength Training: A Retrospective Program Review.","authors":"Elizabeth Sharp Edens, Heather Falise, Rebecca Smith, Elle Bernardo","doi":"10.1002/osp4.70140","DOIUrl":"10.1002/osp4.70140","url":null,"abstract":"<p><strong>Background: </strong>GLP-1 RAs are effective in treating obesity; however, they typically result in significant loss of skeletal muscle mass. Real-world evidence to inform systematic guidelines and clinical implementation for preserving skeletal muscle mass and reducing cardiometabolic risk with lifestyle modifications on GLP-1 RAs remains limited.</p><p><strong>Objective: </strong>This study evaluated the effectiveness of the TouchCare Method, a lifestyle intervention incorporating nutrition and exercise with GLP-1 RAs, for improving body composition and cardiometabolic risk.</p><p><strong>Methods: </strong>A retrospective chart review included patients enrolled in Bucks Health and Wellness between February 2024 and September 2025, for at least 12 month (<i>n</i> = 187). The TouchCare Method incorporates registered dietitian counseling, progressive exercise programming, mobile self monitoring, and body composition analysis during visits. Primary outcomes included: clinically significant weight loss (> 10% of body weight), proportion of weight loss from skeletal muscle mass, and changes in total-C, LDL-C, Apolipoprotein B, Triglycerides, HbA1c, and blood pressure at 12 months.</p><p><strong>Results: </strong>Patients adherent to the TouchCare Method for 12 months were included in the final analysis (<i>n</i> = 171). Clinically significant weight loss (≥ 10%) was achieved by 69.56% (<i>n</i> = 139) of patients. Skeletal muscle mass accounted for 12.22% ± 8.73% of total weight loss. Among prediabetic patients (<i>n</i> = 95), 74.7% (<i>n</i> = 71) reached euglycemia by 12 months. Patients with Stage II hypertension or higher (77% of the cohort) demonstrated improved blood pressure control, with most reaching < 140/90 mmHg. Patients with HLD experienced significant reductions in Total-C (24.71 ± 23.31 mg/dL), LDL-C (-13.75 ± 21.51 mg/dL), and ApoB (-14.24 ± 16.19 mg/dL). All lipid and HgA1c changes were statistically significant (<i>p</i> < 0.001).</p><p><strong>Conclusion: </strong>The TouchCare Method may improve GLP-1 RA treatment outcomes by providing comprehensive structured lifestyle interventions supporting clinically significant weight loss while preserving skeletal muscle mass and improving cardiometabolic risk factors.</p>","PeriodicalId":19448,"journal":{"name":"Obesity Science & Practice","volume":"12 2","pages":"e70140"},"PeriodicalIF":2.5,"publicationDate":"2026-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13052065/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147633951","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bariatric Surgery and Gender Differences in Depressive Symptoms-A 5-Year Prospective Study of Preoperative Predictors.","authors":"Liliana Buer, Ingela Lundin Kvalem, Tom Mala","doi":"10.1002/osp4.70120","DOIUrl":"10.1002/osp4.70120","url":null,"abstract":"<p><strong>Objective: </strong>Candidates for metabolic bariatric surgery (MBS) often exhibit a higher prevalence of depressive symptoms compared with the general population. Studies have shown improvements in depressive symptoms and a reduction in depression prevalence during the initial years following MBS. However, reports on the long-term maintenance of these improvements are conflicting, and factors such as preoperative predictors and gender differences remain poorly understood.</p><p><strong>Methods: </strong>Data were collected from 210 subjects pre-MBS and at 1- and 5-years post-MBS. Health care providers measured Body Mass Index (BMI). All other data were collected via self-report (questionnaires). Pre-MBS factors assumed associated with depressive symptoms at 5 years included BMI, body dissatisfaction, appearance orientation, resilience, and outcome expectancies.</p><p><strong>Results: </strong>The sample comprised 77.6% women. Pre-MBS there were no significant gender differences in depressive symptomatology or the likelihood of being depressed. At both one and 5 years post-MBS, a higher proportion of men were categorized as probably depressed. From baseline to 5 years post-MBS, depressive symptoms declined among women, whereas there was no change among men. Regardless of gender, preoperative depressive symptoms and resilience predicted postoperative depression. Among women, preoperative body dissatisfaction and expectations regarding weight change and appearance were initially associated with postoperative levels of depression.</p><p><strong>Conclusions: </strong>Contrasting common findings, this study identified higher rates of post-surgery depression in men than in women. Furthermore, the results indicate that post-surgery depression may be bivariately associated with different factors depending on gender, although resilience predicted depressive symptoms irrespective of gender.</p>","PeriodicalId":19448,"journal":{"name":"Obesity Science & Practice","volume":"12 2","pages":"e70120"},"PeriodicalIF":2.5,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13042490/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147609457","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Attitudes Toward Injectable GLP-1 Drugs for Obesity Treatment: A Qualitative Interview Study With Healthcare Professionals.","authors":"Raluca C Capaian, Phillippa Lally, Saskia C Sanderson","doi":"10.1002/osp4.70130","DOIUrl":"10.1002/osp4.70130","url":null,"abstract":"<p><strong>Background: </strong>Injectable GLP-1 drugs such as semaglutide (Wegovy) and tirzepatide (Mounjaro, a dual GLP-1 and GIP receptor agonist) can help individuals living with obesity to lose weight. UK guidelines currently recommend semaglutide and other injectable GLP-1 drugs are prescribed in specialist (Tier 3) multidisciplinary weight management services, and other settings. The study aimed to explore the views of healthcare professionals, working within a specialist weight management service that was not yet prescribing injectable GLP-1 drugs, about these drugs being prescribed in their service in the future.</p><p><strong>Methods: </strong>In-depth interviews were conducted with 11 healthcare professionals; thematic analysis was used to identify themes.</p><p><strong>Results: </strong>Thirteen main themes were identified within four theme clusters. <i>Knowledge</i>: (1) knowledge sources; (2) levels of current understanding. <i>Perceived benefits</i>: the drugs (3) might increase patients' confidence in their ability to lose weight and (4) provide a valuable middle ground treatment option between interpersonal behavioral support and bariatric surgery. <i>Concerns</i>: (5) patients might gain weight when they stop taking the drugs; the drugs might (6) mask behavioral patterns, (7) decrease patients' engagement with interpersonal behavior change support, and (8) have mental health risks. <i>Service provision considerations</i>: providing interpersonal behavior change support (9) before, (10) alongside, and (11) after stopping drug prescriptions were provided, (12) the drug prescription pathway is experimental, and (13) the role of healthcare professionals in specialist weight management services is evolving.</p><p><strong>Conclusions: </strong>The findings highlight several areas for further research and practice, including how specialist weight management service teams might integrate interpersonal behavioral support and injectable GLP-1 drug prescriptions to best help patients in the future.</p>","PeriodicalId":19448,"journal":{"name":"Obesity Science & Practice","volume":"12 2","pages":"e70130"},"PeriodicalIF":2.5,"publicationDate":"2026-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13494737/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148795968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Do Commercial Airline Policies for Passengers With Obesity Carry Enough Weight?","authors":"Tom McGovern, Francis M Finucane, Gerard T Flaherty","doi":"10.1002/osp4.70132","DOIUrl":"10.1002/osp4.70132","url":null,"abstract":"<p><strong>Introduction: </strong>The travel industry has a responsibility to accommodate the needs of all its customers, including those with obesity. It is not known to what extent airlines communicate accessibility policies to passengers with obesity. We sought to assess the adequacy and content of information provided by international commercial airlines regarding the carriage of passengers with obesity.</p><p><strong>Methods: </strong>A descriptive cross-sectional analysis was conducted of policies relating to passengers with obesity that were available on publicly accessible websites of the 50 busiest global commercial airlines. Variables of interest included fleet description, passenger weight-related terminology, seating information, use of seatbelt extenders, special assistance information, use of artificial intelligence chatbots for customer service, and availability of customer information in the English language.</p><p><strong>Results: </strong>A diverse range of terms was used to describe travelers with obesity, with \"customers requiring extra personal space\" or \"an extra seat for personal comfort\" being the most frequently used descriptors. Seating information relating to larger passengers was provided by 86% (<i>n</i> = 43) of airlines. Passenger guidance on the use of seatbelt extenders was available on 70% (<i>n</i> = 35) of airline websites. Special assistance information was provided by all airlines.</p><p><strong>Conclusion: </strong>While leading commercial airlines provide obesity policy information on their websites, there is considerable variation between carriers in the degree of information provided. There is a need for more transparent and standardized accessibility information for airline passengers with obesity.</p>","PeriodicalId":19448,"journal":{"name":"Obesity Science & Practice","volume":"12 2","pages":"e70132"},"PeriodicalIF":2.5,"publicationDate":"2026-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12977105/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147444515","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Obesity-Related Beliefs, Concerns, and Stigmatizing Perceptions Among Adults Living With Obesity.","authors":"Luiz F Viola, Cynthia M Valerio, Raquel B G Muniz, Roberta M C Moreira Allgayer, Thaisa D G Trujilho, Alexandre Hohl, Rodrigo N Lamounier, Maria Augusta Bernardini, Roberta Brito, Bruno Halpern, Fábio R Trujilho","doi":"10.1002/osp4.70133","DOIUrl":"10.1002/osp4.70133","url":null,"abstract":"<p><strong>Background: </strong>Weight stigma represents a barrier to effective obesity management and to achieving health equity. Although most research has focused on high-income countries, data from Latin America remain scarce. This study aimed to examine perceptions, beliefs, and concerns about obesity among adults living with obesity in a middle-income country.</p><p><strong>Methods: </strong>This subanalysis used data from a nationally representative survey investigating perceptions of obesity among 2560 adults residing in Brazil. Responses from 653 people living with obesity (body mass index ≥ 30 kg/m²) were included in the present analysis. Analyses were stratified by gender and obesity class.</p><p><strong>Findings: </strong>Stigmatizing beliefs were prevalent: 27.5% of participants agreed that people living with obesity are personally responsible for their weight, with a significantly higher prevalence among men (35.5%, <i>p</i> < 0.001). Among those with Class II obesity, 42.8% of men and 15.0% of women endorsed this belief (<i>p</i> < 0.001). Leisure environments (48.2%) were the most frequently reported settings of discrimination, followed by workplaces (33.4%) and public transportation (33.1%). Healthcare settings were also cited by 11.6% of the responses. The most commonly reported sources of obesity-related information were healthcare professionals (50.3%) and those professionals active on social media (39.3%).</p><p><strong>Interpretation: </strong>Stigmatizing attitudes and the attribution of personal blame toward people living with obesity are widespread in Brazil. These findings underscore the need to integrate stigma awareness into medical education, public health communication, and clinical practice. Leveraging trusted sources, including healthcare professionals and influential social media communicators, may help mitigate weight stigma.</p>","PeriodicalId":19448,"journal":{"name":"Obesity Science & Practice","volume":"12 2","pages":"e70133"},"PeriodicalIF":2.5,"publicationDate":"2026-03-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12971610/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147434478","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Health Behaviors Associated With Overweight and Obesity Among Physicians.","authors":"Dana Kagansky, Racheli Magnezi, Shlomit Koren, Matan Elkan, Orna Tal","doi":"10.1002/osp4.70129","DOIUrl":"10.1002/osp4.70129","url":null,"abstract":"<p><strong>Background: </strong>Overweight and obesity among physicians are increasingly recognized as relevant to workforce health, quality of care, and the credibility of lifestyle counseling delivered to patients. Physicians may face constraints that affect dietary patterns, physical activity, and daily routine, behaviors directly related to BMI. However, data linking specific lifestyle behaviors to BMI in this population remain limited.</p><p><strong>Objective: </strong>To examine associations between self-reported health behaviors and BMI among physicians and outline implications for workplace wellness.</p><p><strong>Methods: </strong>Cross-sectional online survey of physicians using the 26-item Healthy Lifestyle and Personal Control Questionnaire (HLPCQ). Participants were categorized into normal weight (BMI < 25) and overweight or obesity (BMI ≥ 25) groups based on their BMI. Group differences and multivariable logistic regression were applied.</p><p><strong>Results: </strong>Of 200 respondents, 144 complete cases were analyzed; 54.2% had a BMI < 25. Higher BMI was associated with lower adherence to health-promoting behaviors, notably Dietary Harm Avoidance (<i>p</i> < 0.01), Daily Routine (<i>p</i> = 0.05), and Organized Physical Exercise (<i>p</i> = 0.03). Regression analysis identified Dietary Harm Avoidance and Organized Physical Exercise as protective factors against overweight and obesity (<i>p</i> < 0.01). Physicians in surgical specialties reported lower health behavior scores than non-surgical peers, particularly in Daily Routine (<i>p</i> < 0.01) and in total lifestyle scores (<i>p</i> = 0.01).</p><p><strong>Conclusions: </strong>Specific lifestyle behaviors, particularly dietary harm avoidance and organized physical activity, were associated with BMI among physicians. These associations may help inform future research on modifiable behavioral factors related to overweight and obesity among physicians.</p>","PeriodicalId":19448,"journal":{"name":"Obesity Science & Practice","volume":"12 2","pages":"e70129"},"PeriodicalIF":2.5,"publicationDate":"2026-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12966352/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147377600","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}